Imagine a breakthrough in cancer treatment where only malignant cells are targeted, sparing healthy host cells; or patients with abnormal protein synthesis are treated to produce a healthy protein.
Expanding treatment horizons for hypermutated urothelial carcinomas beyond immunotherapy
A new editorial paper was published in Oncoscience (Volume 11) on April 25, 2024, entitled, “Therapeutic opportunities for hypermutated urothelial carcinomas beyond immunotherapy.”
May 11, 2024